Joint Shared Care Guidelines

Drug

Tinzaparin Injection pre-filled syringes 3,500 units/0.35mL & 4,500 units/0.45mL

Specialty

Obstetrics

Indication

Prophylaxis for Venous Thromboembolism (VTE) in ante- and post-natal women (high risk)

Overview

Tinzaparin is a low molecular weight heparin (LMWH) given by subcutaneous injection once a day, and is used in both ante and post-natal situations for prevention of VTE, for those defined as high risk after assessment of the risk and benefit as defined by RCOG (Royal College of Obstetrics and Gynaecology) guidance. Note this is an off licence indication, however it is recommended by RCOG national guidance.

Hospital specialist's responsibilities Initial investigations: Assessment of risk and benefit, decision to treat.

Initial regimen: Daily by sub-cutaneous injection for the duration of the risk

determined by risk assessment tool

Dose banded dosing:

<50kg = 3500 units per day = 4500 units per day 50-90kg 91-130kg = 3500 units twice daily

131-170kg = 4500 units twice daily (or 9000 units once daily) = 75 units/kg/day (can be split in 2 divided doses) >170kg

Clinical monitoring: None required except in at risk groups. Monitoring then

recommended monthly

Safety monitoring: Full blood count completed at antenatal booking appointment.

Platelets and potassium to be monitored only if any concern

highlighted in initial blood screening. Renal function to be monitored

if patient known to have any renal condition or impairment.

Prescribing Initial 30 day supply from hospital (with sharps bin). Further arrangements: supplies from hospital or prescribing midwife if convenient for the

patient. In all other situations to be supplied by GP as per shared

care agreement.

Documentation: **Documentation for GP:**

Other:

Risk assessment and initial regimen documented at hospital Completion of GP recommendation form if requesting GP to

provide further supplies

Provision of patient education, counselling and information

GP's responsibilities

Prescribing As above

Clinical monitoring: None required

Safety monitoring: Only at the agreed request of the hospital specialist

Duration of treatment: As defined in GP recommendation form

Documentation: Record of supplies only

Adverse events

	Adverse Event	Action
	Thrombocytopenia	If platelets fall below 50% of baseline count discontinue
		immediately and refer for emergency assessment for Heparin Induced
		Thrombocytopenia (HIT)
	Hyperkalaemia	If potassium rises above 5.5mmol/L, inform specialist promptly and
		seek advice regarding continuation of therapy.
	Allergy to a	Discontinue immediately and inform specialist promptly.
	component	

Other information

Contact details

Refer to the Summary of Product Characteristics (SPC) for a full list of adverse effects, and the current BNF for up to date prescribing information.

Name: GMC No:

Address: Telephone No:

Date approved: November 2019 Review date: November 2021